An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Conditions

• Non-Hodgkin Lymphoma, Follicular Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Mosunetuzumab SC — DRUG
  Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
• Tiragolumab — DRUG
  Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
• Atezolizumab — DRUG
  Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
• Tocilizumab — OTHER
  Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events

Study Details

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.

Key Dates

Start date

May 10, 2022

Status verified

Sep 2024

Primary completion

Jul 19, 2023

Completion

Jul 19, 2023

Study Design

Enrollment

8 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab
  Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
• Experimental: Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV
  Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days) Note: This arm did not enroll any participants.

Primary Outcome Measure

Percentage of Participants With Adverse Events - Phase 1b [ Time Frame: From the start of treatment until 90 days after the final dose of study treatment (up to 36 weeks) ]

Locations (3)

Find similar trials in Los Angeles, CA